Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Recursion Pharmaceuticals, Inc.

NASDAQ: RXRX · Life Sciences · 7 alerts · CIK 1601830

Share price
$2.90Close, Nov 16
Market cap
$1.81B
Shares outstanding
622.76MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Recursion Pharmaceuticals, Inc. filings on SEC EDGAR ↗

4:34 PM ET 10-Q
Financial Results

Recursion Pharmaceuticals Q3 2026 Results: Net Loss of $119M, Loss Narrows

Recursion Pharmaceuticals reported a net loss of $119.0 million for the third quarter of 2026, an improvement from the $162.3 million loss in the prior year period. Total revenue increased significantly to $18.6 million for the quarter, while the company maintained a strong liquidity position with $549.9 million in cash and cash equivalents as of September 30, 2026.

Key figure
Net loss $119M
4:33 PM ET 8-K
Financial Results

Recursion Pharmaceuticals Financial Results

Recursion Pharmaceuticals reported Q3 2026 financial results, highlighting clinical data for REC-4881 and REC-1245 and the appointment of Fred Hassan as Chair of the Board. The company extended its cash runway into 2029 following an October follow-on offering and noted that Sanofi has optioned the first development candidate from their collaboration.

Term
Q3 2026

“To pioneer a new blueprint for making medicines with AI, we believe you have to tie together three core capabilities in one engine: uncover novel biology, design differentiated molecules against challenging targets, and generate clinical evidence that matters for patients.”

Najat Khan, Ph.D., President and Chief Executive Officer of Recursion

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.